Expertises :
- Clinique:Biochimie et Biologie Moléculaire
- Recherche:Pharmacologie
- Recherche:Biologie Moléculaire
- Recherche:Modèle animaux
- Cancer:Colorectal
- Plateforme:Xénogreffes

Projets

Plate-forme mutualisée de séquençage de nouvelle génération somatique et constitutionnelle de l’Institut Régional du Cancer d’Alsace (IRECAL)

2013 - Porteur du projet : Pr MAUVIEUX Laurent - Partenaires : Pr ABECASSIS Joseph, Dr GAUB Marie-Pierre, Dr GUERIN Eric, Pr MANDEL Jean-Louis

Early determination of aggressiveness of primary tumors (RIO2007)

2007 - Porteur du projet : Dr RIO Marie-Christine - Partenaires : Pr ABECASSIS Joseph, Pr BIREMBAUT Philippe, Pr DIEBOLD Marie-Danièle, Dr FREUND Jean-Noël, Dr GAUB Marie-Pierre, Dr GHNASSIA Jean-Pierre, Dr GUERIN Eric, Pr HAIECH Jacques, Pr JEANNESSON Pierre, Dr KASTNER Philippe, Pr MANFAIT Michel, Pr MAQUART François-Xavier, Dr NEUVILLE Agnès, Dr OREND Gertraud, Pr PLENAT François, Dr VAN DORSSELAER Alain, Pr VIGNAUD Jean-Michel, Dr VOEGEL Jean-Claude, Dr WASYLYK Bohdan

Publications

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.

Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilié M

ESMO Open. 2023 09 13;8(5):101628

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances.

Geyer L, Wolf T, Chenard MP, Cebula H, Schott R, Noel G, Guerin E, Pencreach E, Reita D, Entz-Werlé N, Lhermitte B

Cancers (Basel). 2023 02 28;15(5):

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.

Lhermitte B, Wolf T, Chenard MP, Coca A, Todeschi J, Proust F, Hirsch E, Schott R, Noel G, Guerin E, Reita D, Chammas A, Salmon A, Martin S, Dontenwill M, Entz-Werlé N

Cancers (Basel). 2023 02 16;15(4):

Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.

Venkatasamy A, Guerin E, Reichardt W, Devignot V, Chenard MP, Miguet L, Romain B, Jung AC, Gross I, Gaiddon C, Mellitzer G

Gastric Cancer. 2022 12 19;:

Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment.

Pierrevelcin M, Flacher V, Mueller CG, Vauchelles R, Guerin E, Lhermitte B, Pencreach E, Reisch A, Muller Q, Doumard L, Boufenghour W, Klymchenko AS, Foppolo S, Nazon C, Weingertner N, Martin S, Briandet C, Laithier V, Di Marco A, Bund L, Obrecht A, Villa P, Dontenwill M, Entz-Werlé N

Adv Healthc Mater. 2022 09 4;:e2200195

Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.

Coutant M, Lhermitte B, Guérin E, Chammas A, Reita D, Sebastia C, Douzal V, Gabor F, Salmon A, Chenard MP, Todeschi J, Coca A, Heng MA, Vincent F, Entz-Werlé N

Pediatr Blood Cancer. 2022 Apr 4;:e29575

Direct Targeting Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M

Cancers (Basel). 2022 Mar 4;14(5):

Molecular Mechanism of EGFR-TKI Resistance in -Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M

Cancers (Basel). 2021 Sep 30;13(19):

Ultrasound and Transcriptomics Identify a Differential Impact of Cisplatin and Histone Deacetylation on Tumor Structure and Microenvironment in a Patient-Derived In Vivo Model of Gastric Cancer.

Venkatasamy A, Guerin E, Blanchet A, Orvain C, Devignot V, Jung M, Jung AC, Chenard MP, Romain B, Gaiddon C, Mellitzer G

Pharmaceutics. 2021 Sep 16;13(9):

A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value.

Entz-Werlé N, Poidevin L, Nazarov PV, Poch O, Lhermitte B, Chenard MP, Burckel H, Guérin E, Fuchs Q, Castel D, Noel G, Choulier L, Dontenwill M, Van Dyck E

Cancers (Basel). 2021 May 7;13(9):

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.

Jannier S, Kemmel V, Sebastia Sancho C, Chammas A, Sabo AN, Pencreach E, Farace F, Chenard MP, Lhermitte B, Geoerger B, Aerts I, Frappaz D, Leblond P, André N, Ducassou S, Corradini N, Bertozzi AI, Guérin E, Vincent F, Velten M, Entz-Werle N

Cancers (Basel). 2020 Oct 20;12(10):

Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability.

Pierrevelcin M, Fuchs Q, Lhermitte B, Messé M, Guérin E, Weingertner N, Martin S, Lelong-Rebel I, Nazon C, Dontenwill M, Entz-Werlé N

Cells. 2020 Aug 31;9(9):

Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric -Mutated Gliomas Recreate the Patient Tumor Complexity.

Blandin AF, Durand A, Litzler M, Tripp A, Guérin É, Ruhland E, Obrecht A, Keime C, Fuchs Q, Reita D, Lhermitte B, Coca A, Jones C, Rebel IL, Villa P, Namer IJ, Dontenwill M, Guenot D, Entz-Werle N

Cancers (Basel). 2019 Nov 26;11(12):

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells.

Reita D, Bour C, Benbrika R, Groh A, Pencreach E, Guérin E, Guenot D

Cancers (Basel). 2019 Oct 17;11(10):

Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on -Driven Oncogenic Addiction.

Job S, Reyniès A, Heller B, Weiss A, Guérin E, Macabre C, Ledrappier S, Bour C, Wasylyk C, Etienne-Selloum N, Brino L, Gaiddon C, Wasylyk B, Jung AC

Cancers (Basel). 2019 Jun 8;11(6):

A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

Vidimar V, Licona C, Camacho RC, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C

Cancer Lett.. 2018 Oct 16;:

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients.

Emprou C, Le Van Quyen P, Jégu J, Prim N, Weingertner N, Guérin E, Pencreach E, Legrain M, Voegeli AC, Leduc C, Mennecier B, Falcoz PE, Olland A, Santelmo N, Quoix E, Massard G, Guenot D, Chenard MP, Beau-Faller M

Cancer Med. 2018 May 29;:

Signaling pathway deregulation and molecular alterations across pediatric medulloblastomas.

Lhermitte B, Blandin AF, Coca A, Guerin E, Durand A, Entz-Werlé N

Neurochirurgie. 2018 May 15;:

A single-nucleotide polymorphism of ABCB1 (MDR1) is correlated with poor response to Imatinib chronic myeloid leukemia.

Glady L, Guerin E, Ame S, Maloisel F, Lessinger JM

Ann. Oncol.. 2017 Oct;28 Suppl 7:vii5-vii6

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition.

Nguyen A, Moussallieh FM, Mackay A, Cicek AE, Coca A, Chenard MP, Weingertner N, Lhermitte B, Letouzé E, Guérin E, Pencreach E, Jannier S, Guenot D, Namer IJ, Jones C, Entz-Werlé N

Oncotarget. 2017 Sep 22;8(42):71597-71617

A compound heterozygote case of isolated sulfite oxidase deficiency.

Brumaru D, Guerin E, Voegeli AC, Eyer D, Maitre M

Mol Genet Metab Rep. 2017 Sep;12:99-102

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1a axis inhibition.

Nguyen A, Moussallieh FM, Mackay A, Cicek AE, Coca A, Pierre Chenard M, Weingertner N, Lhermitte B, Letouzé E, Guérin E, Pencreach E, Jannier S, Guenot D, Jacques Namer I, Jones C, Entz-Werlé N

Oncotarget. 2017 Mar;:

Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.

Renaud S, Schaeffer M, Voegeli AC, Legrain M, Guérin E, Meyer N, Mennecier B, Quoix E, Falcoz PE, Guénot D, Massard G, Noël G, Beau-Faller M

Future Oncol. 2016 Jan;12(1):59-70

Integrin alpha5beta1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.

Renner G, Janouskova H, Noulet F, Koenig V, Guerin E, Bar S, Nuesch J, Rechenmacher F, Neubauer S, Kessler H, Blandin AF, Choulier L, Etienne-Selloum N, Lehmann M, Lelong-Rebel I, Martin S, Dontenwill M

Cell Death Differ. 2015 Oct 16

IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Rizzo D, Chauzeix J, Trimoreau F, Woillard JB, Genevieve F, Bouvier A, Labrousse J, Poli C, Guerin E, Dmytruk N, Remenieras L, Feuillard J, Gachard N

Leukemia. 2015 Feb;29(2):337-45

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients.

Prim N, Legrain M, Guerin E, Mennecier B, Weingertner N, Voegeli AC, Guenot D, Maugard CM, Quoix AE, Beau-Faller M

Eur Respir Rev. 2014 Sep;23(133):390-2

Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.

Petitprez A, Poindessous V, Ouaret D, Regairaz M, Bastian G, Guerin E, Escargueil AE, Larsen AK

Int J Oncol. 2013 May;42(5):1644-53

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse.

Nguyen A, Lasthaus C, Guerin E, Marcellin L, Pencreach E, Gaub MP, Guenot D, Entz-Werle N

Cancers (Basel). 2013 Jun 4;5(2):662-75

Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.

Pinel S, Mriouah J, Vandamme M, Chateau A, Plenat F, Guerin E, Taillandier L, Bernier-Chastagner V, Merlin JL, Chastagner P

PLoS One. 2013 Jul 18;8(7):e68333

Involvement of the TGFbeta pathway in the regulation of alpha5 beta1 integrins by caveolin-1 in human glioblastoma.

Cosset EC, Godet J, Entz-Werle N, Guerin E, Guenot D, Froelich S, Bonnet D, Pinel S, Plenat F, Chastagner P, Dontenwill M, Martin S

Int J Cancer. 2012 Aug 1;131(3):601-11

A cytogenetic study of 397 consecutive acute myeloid leukemia cases identified three with a t(7;21) associated with 5q abnormalities and exhibiting similar clinical and biological features, suggesting a new, rare acute myeloid leukemia entity.

Jeandidier E, Gervais C, Radford-Weiss I, Zink E, Gangneux C, Eischen A, Galoisy AC, Helias C, Dano L, Cammarata O, Jung G, Harzallah I, Guerin E, Martzolff L, Drenou B, Lioure B, Tancredi C, Rimelen V, Mauvieux L

Cancer Genet. 2012 Jul-Aug;205(7-8):365-72

Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.

Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guerin E, Guenot D, Pinel S, Chastagner P, Plenat F, Entz-Werle N, Lehmann-Che J, Godet J, Martin S, Teisinger J, Dontenwill M

Cancer Res. 2012 Jul 15;72(14):3463-70

Pyridylthiourea-grafted polyethylenimine offers an effective assistance to siRNA-mediated gene silencing in vitro and in vivo.

Creusat G, Thomann JS, Maglott A, Pons B, Dontenwill M, Guérin E, Frisch B, Zuber G

J Control Release. 2012 Feb;157(3):418-26

In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1alpha target genes and decreases tumor angiogenesis.

Guerin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, Gaub MP, Guenot D

Mol Med. 2012 Feb 10;18(1):83-94

Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.

Rebucci M, Peixoto P, Dewitte A, Wattez N, De Nuncques MA, Rezvoy N, Vautravers-Dewas C, Buisine MP, Guerin E, Peyrat JP, Lartigau E, Lansiaux A

Int J Oncol. 2011 Jan;38(1):189-200.

CDX2 in congenital gut gastric-type heteroplasia and intestinal-type Meckel diverticula.

Martin E, Vanier M, Tavian M, Guerin E, Domon-Dell C, Duluc I, Gross I, Rowland J, Kim S, Freund JN

Pediatrics. 2010 Sep;126(3):e723-7

The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators.

Rocca CJ, Poindessous V, Soares DG, Ouadrani KE, Sarasin A, Guerin E, de Gramont A, Henriques JA, Escargueil AE, Larsen AK

Biochem Pharmacol. 2010 Aug 1;80(3):335-43

Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease.

Entz-Werle N, Choquet P, Neuville A, Kuchler-Bopp S, Clauss F, Danse JM, Simo-Noumbissie P, Guerin E, Gaub MP, Freund JN, Boehm N, Constantinesco A, Lutz P, Guenot D, Perrin-Schmitt F

Transl Oncol. 2010 Dec 1;3(6):344-53.

Evidence for various 20q status using allelotyping, CGH arrays, and quantitative PCR in distal CIN colon cancers.

Nicolet C, Guerin E, Neuville A, Kerckaert JP, Wicker N, Bergmann E, Brigand C, Kedinger M, Gaub MP, Guenot D

Cancer Lett. 2009 Sep 18;282(2):195-204

Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping.

Beau-Faller M, Legrain M, Voegeli AC, Guerin E, Lavaux T, Ruppert AM, Neuville A, Massard G, Wihlm JM, Quoix E, Oudet P, Gaub MP

Br J Cancer. 2009 Mar 24;100(6):985-92.

Genetic compensation in a human genomic disorder.

Carelle-Calmels N, Saugier-Veber P, Girard-Lemaire F, Rudolf G, Doray B, Guerin E, Kuhn P, Arrive M, Gilch C, Schmitt E, Fehrenbach S, Schnebelen A, Frebourg T, Flori E

N Engl J Med. 2009 Mar 19;360(12):1211-6.

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.

Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E

Eur Respir J. 2009 Feb;33(2):436-40.

Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.

Pencreach E, Guerin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D

Clin Cancer Res. 2009 Feb 15;15(4):1297-307

Proximal 15q familial euchromatic variant and PWS/AS critical region duplication in the same patient: a cytogenetic pitfall.

Carelle-Calmels N, Girard-Lemaire F, Guerin E, Bieth E, Rudolf G, Biancalana V, Pecheur H, Demil H, Schneider T, de Saint-Martin A, Caron O, Legrain M, Gaston V, Flori E

Eur J Med Genet. 2008 Nov-Dec;51(6):547-57

MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort

Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP

J Thorac Oncol. 2008 Apr;3(4):331-9.

Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab?

Entz-Werle N, Velasco V, Neuville A, Geoerger B, Mathieu MC, Guerin E, Kehrli P, Gaub MP, Vassal G, Grill J

Pediatr Blood Cancer. 2008 Jan;50(1):163-6.

Frequent rearrangements and amplification of the CDX2 homeobox gene in human sporadic colorectal cancers with chromosomal instability.

Subtil C, Guerin E, Schneider A, Chenard MP, Martin E, Domon-Dell C, Duluc I, Brabletz T, Kedinger M, Duclos B, Gaub MP, Freund JN

Cancer Lett. 2007 Mar 18;247(2):197-203

Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes.

Weber JC, Meyer N, Pencreach E, Schneider A, Guerin E, Neuville A, Stemmer C, Brigand C, Bachellier P, Rohr S, Kedinger M, Meyer C, Guenot D, Oudet P, Jaeck D, Gaub MP

Int J Cancer. 2007 Feb 1;120(3):524-32.

SAGETTARIUS: a program to reduce the number of tags mapped to multiple transcripts and to plan SAGE sequencing stages.

Bianchetti L, Wu Y, Guerin E, Plewniak F, Poch O

Nucleic Acids Res. 2007;35(18):e122

Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability.

Guenot D, Guerin E, Aguillon-Romain S, Pencreach E, Schneider A, Neuville A, Chenard MP, Duluc I, Du Manoir S, Brigand C, Oudet P, Kedinger M, Gaub MP

J Pathol. 2006 Apr;208(5):643-52.

Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases.

Dive V, Andarawewa KL, Boulay A, Matziari M, Beau F, Guerin E, Rousseau B, Yiotakis A, Rio MC

Int J Cancer. 2005 Feb 20;113(5):775-81.

Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression.

Beau-Faller M, Gaub MP, Schneider A, Guérin E, Meyer N, Ducrocq X, Massard G, Gasser B, Kessler R, Weitzenblum E, Wihlm JM, Quoix E, Oudet P

Eur. J. Cancer. 2003 Nov;39(17):2538-47

Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics.

Stemmer C, Beau-Faller M, Pencreac'h E, Guerin E, Schneider A, Jaqmin D, Quoix E, Gaub MP, Oudet P

Clin Chem. 2003 Nov;49(11):1953-5.

Cdx1 homeobox gene during human colon cancer progression.

Domon-Dell C, Schneider A, Moucadel V, Guerin E, Guenot D, Aguillon S, Duluc I, Martin E, Iovanna J, Launay JF, Duclos B, Chenard MP, Meyer C, Oudet P, Kedinger M, Gaub MP, Freund JN

Oncogene. 2003 Sep 11;22(39):7913-21.

Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia.

Guerin E, Entz-Werle N, Eyer D, Pencreac'h E, Schneider A, Falkenrodt A, Uettwiller F, Babin A, Voegeli AC, Lessard M, Gaub MP, Lutz P, Oudet P

Leukemia. 2003 Mar;17(3):532-40.